JP2016517402A5 - - Google Patents

Download PDF

Info

Publication number
JP2016517402A5
JP2016517402A5 JP2015562395A JP2015562395A JP2016517402A5 JP 2016517402 A5 JP2016517402 A5 JP 2016517402A5 JP 2015562395 A JP2015562395 A JP 2015562395A JP 2015562395 A JP2015562395 A JP 2015562395A JP 2016517402 A5 JP2016517402 A5 JP 2016517402A5
Authority
JP
Japan
Prior art keywords
recombinant
growth factor
protein according
synthetic protein
vegf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015562395A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016517402A (ja
JP6873530B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2014/001125 external-priority patent/WO2014140894A2/en
Publication of JP2016517402A publication Critical patent/JP2016517402A/ja
Publication of JP2016517402A5 publication Critical patent/JP2016517402A5/ja
Application granted granted Critical
Publication of JP6873530B2 publication Critical patent/JP6873530B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015562395A 2013-03-15 2014-03-17 自己組織化合成タンパク質(Self−Assembling Synthetic Proteins) Expired - Fee Related JP6873530B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361791268P 2013-03-15 2013-03-15
US61/791,268 2013-03-15
PCT/IB2014/001125 WO2014140894A2 (en) 2013-03-15 2014-03-17 Self-assembling synthetic proteins

Publications (3)

Publication Number Publication Date
JP2016517402A JP2016517402A (ja) 2016-06-16
JP2016517402A5 true JP2016517402A5 (enExample) 2017-03-23
JP6873530B2 JP6873530B2 (ja) 2021-05-19

Family

ID=51225849

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015562395A Expired - Fee Related JP6873530B2 (ja) 2013-03-15 2014-03-17 自己組織化合成タンパク質(Self−Assembling Synthetic Proteins)

Country Status (14)

Country Link
US (3) US10736948B2 (enExample)
EP (1) EP2970409A2 (enExample)
JP (1) JP6873530B2 (enExample)
KR (2) KR102391734B1 (enExample)
CN (2) CN111978409B (enExample)
AU (1) AU2014229561B2 (enExample)
BR (1) BR112015023402A2 (enExample)
CA (1) CA2904506A1 (enExample)
HK (1) HK1214606A1 (enExample)
IL (3) IL286537B (enExample)
MX (2) MX385451B (enExample)
MY (1) MY187936A (enExample)
RU (1) RU2747857C2 (enExample)
WO (1) WO2014140894A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160333087A1 (en) 2015-05-12 2016-11-17 Bioven 3 Limited Methods and compositions for inhibition of egf/egfr pathway in combination with tyrosine kinase inhibitors
JP7751357B2 (ja) * 2017-07-18 2025-10-08 イン3バイオ・リミテッド 合成タンパク質およびその治療学的用途
WO2020257317A1 (en) * 2019-06-18 2020-12-24 Citranvi Biosciences, Llc Rationally engineered carrier proteins for vaccines
KR20220058527A (ko) * 2019-06-25 2022-05-09 인3바이오 리미티드 안정화된 키메라 합성 단백질 및 그 치료 용도
KR20220099990A (ko) 2019-11-07 2022-07-14 인3바이오 리미티드 비티로신 표적화 키나아제 억제제와 병용하여 성장 인자 항체를 사용하기 위한 방법 및 조성물
CN114019166B (zh) * 2021-09-27 2024-02-27 浙江省食品药品检验研究院 一种检测龙葵素的试纸条及其应用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3238190A (en) 1963-10-23 1966-03-01 Madaus & Co K G Fa Dr Aescin recovery
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US6153203A (en) 1993-10-08 2000-11-28 Duotol Ab Immunological tolerance-inducing agent
ES2237750T3 (es) * 1993-12-09 2005-08-01 Centro De Inmunologia Molecular Vacuna que comprende factor de crecimiento epidermico autologo humano y su uso.
CA2261433A1 (en) * 1993-12-09 1995-06-10 Belinda Sanchez Ramirez Composition comprising autologous epidermal growth factor
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
BR9712852A (pt) * 1996-10-23 1999-11-16 Univ Pennsylvania Plasmìdeo, composição, processo de imunização de um indivìduo contra um patógeno, vacina recombinante, patógeno vivo atenuado, proteìna bl-1 substancialmente pura, vetor recombinante de expressão, e, anticorpo isolado
ES2500490T3 (es) 1997-08-29 2014-09-30 Antigenics Inc. Composiciones que comprenden el adyuvante QS-21 y polisorbato o ciclodextrina como excipiente
US20080249019A1 (en) * 1998-08-25 2008-10-09 Syntaxin, Ltd. Treatment of mucus hypersecretion
CN1227030C (zh) 1999-04-19 2005-11-16 史密丝克莱恩比彻姆生物有限公司 包含皂甙和免疫刺激寡核苷酸的佐剂组合物
SK782002A3 (en) * 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
WO2001027144A2 (en) 1999-10-08 2001-04-19 Active Biotech Ab Ab5 toxin b subunit mutants with altered chemical conjugation characteristics
PE20020572A1 (es) * 2000-12-06 2002-07-31 Centro Inmunologia Molecular Preparaciones para potenciar la inmunogenicidad de antigenos poco inmunogenicos
US6991849B2 (en) 2001-06-21 2006-01-31 Teijin Limited Near infrared ray shielding film
GB0115382D0 (en) 2001-06-22 2001-08-15 Univ Bristol Mutant
JP2005512538A (ja) * 2001-12-14 2005-05-12 セントカー・インコーポレーテツド 無血清培地中でタンパク質を製造するのに有用なクローン性骨髄腫細胞系
ATE372379T1 (de) * 2002-03-15 2007-09-15 Cellectis Hybride and einzelkettige meganukleasen und deren anwendungen
DE602004031341D1 (de) * 2003-07-21 2011-03-24 Transgene Sa Multifunktionelle cytokine
JP4623625B2 (ja) 2003-07-24 2011-02-02 株式会社AMBiS ヘテロ型5量体組換えワクチン
US7320795B2 (en) * 2003-07-30 2008-01-22 Vaccine Research Institute Of San Diego Rodent hepatitis B virus core proteins as vaccine platforms and methods of use thereof
ATE541580T1 (de) * 2003-12-05 2012-02-15 Univ Northwestern Selbst anordnende peptid-amphiphile und relevante verfahren für die abgabe von wachstumsfaktor
NZ549048A (en) 2004-02-11 2009-04-30 Angeletti P Ist Richerche Bio Carcinoembryonic antigen fusion proteins and uses thereof
EP1921149A1 (en) * 2006-11-13 2008-05-14 AEterna Zentaris GmbH Microorganisms as carriers of nucleotide sequences coding for antigens and protein toxins, process of manufacturing and uses thereof
US7946815B2 (en) 2007-03-27 2011-05-24 Siemens Energy, Inc. Airfoil for a gas turbine engine
CN101970498A (zh) 2007-10-25 2011-02-09 维文蒂阿生物技术公司 针对变体HnRNPG的癌相关表位的抗体及其应用
WO2009078796A1 (en) 2007-12-19 2009-06-25 Mivac Development Aktiebolag Compositions and methods for treatment of autoimmune and allergic diseases
AU2009265095B2 (en) 2008-06-09 2014-09-11 Bharat Biotech International Limited Vaccine composition useful for HPV and Hepatitis B infections and a method for preparing the same
JP2010050586A (ja) 2008-08-20 2010-03-04 Nec Corp 通信装置及びそれに用いる装置コンポーネント複合冗長化方法
JPWO2010050586A1 (ja) * 2008-10-31 2012-03-29 ディナベック株式会社 組み換え蛋白質の発現を増強する方法
KR20110104032A (ko) * 2008-12-19 2011-09-21 마크로제닉스, 인크. 공유결합형 디아바디 및 이의 용도
JP2011097930A (ja) * 2009-10-07 2011-05-19 Hokkaido Univ 光活性化生理機能センサータンパク質
RU2480524C2 (ru) * 2010-09-13 2013-04-27 Учреждение Российской академии наук Институт биоорганической химии им. академии М.М. Шемякина и Ю.А. Овчинникова РАН Конструкция на основе белковой пары барназа-барстар и способ ее получения
ES2676878T3 (es) * 2011-03-03 2018-07-25 Zymeworks Inc. Diseño de armazón de heteromultímero multivalente y constructos
CN102604993B (zh) 2012-01-10 2013-03-20 天津耀宇生物技术有限公司 免疫佐剂与幽门螺杆菌抗原融合蛋白口服疫苗及其制备方法

Similar Documents

Publication Publication Date Title
JP2016517402A5 (enExample)
HRP20201282T1 (hr) Rekombinantni proteini i njihove terapeutske upotrebe
van Riet et al. Mucosal IgA responses in influenza virus infections; thoughts for vaccine design
RU2015143217A (ru) Самособирающиеся синтетические белки
Kim et al. Multiple heterologous M2 extracellular domains presented on virus-like particles confer broader and stronger M2 immunity than live influenza A virus infection
BR112018012962A2 (pt) vacinas de zika recombinantes
HRP20100228T1 (hr) Modificirani hekson protein adenovirusa i njegove uporabe
JP2015096070A5 (enExample)
JP2020517635A5 (enExample)
JP2014510519A5 (enExample)
JP2017029157A5 (enExample)
JP2010519931A5 (enExample)
ME02652B (me) Stabilizovana varijanta aktivin iib receptora
HRP20211926T1 (hr) Konstrukti proteina uspa2 i njihova upotreba
JP2017511140A5 (enExample)
Kim et al. Influenza M2 virus-like particles confer a broader range of cross protection to the strain-specific pre-existing immunity
UY37405A (es) Vectores de adenovirus canino
JP2018531624A5 (enExample)
KR20230154048A (ko) Sbi 어쥬번트를 포함하는 조성물 및 이들의 이용 방법
WO2016116905A9 (en) Cmv antigens and uses thereof
JP2009500298A5 (enExample)
RU2015106916A (ru) Полипептиды clostridium difficile в виде вакцины
JP2020509770A5 (enExample)
JP2015529677A5 (enExample)
Yang et al. Protection against influenza H7N9 virus challenge with a recombinant NP–M1–HSP60 protein vaccine construct in BALB/c mice